Swedish Orphan Biovitrum (BIOVF) Stock Price, News & Analysis

Company Overview

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions. Sobi also holds commercialization rights to Synagis (palivizumab) for the prevention of severe respiratory syncytial virus in infants under agreements with AstraZeneca. In addition to these flagship products, the firm maintains a diverse pipeline of biologics, small molecules and orphan drug candidates in various stages of clinical development.

Sobi operates through a network of subsidiaries and partnerships across Europe, North America and selected international markets. The company’s commercial infrastructure includes direct sales forces in key regions and collaborations with pharmaceutical partners to extend geographic reach. Manufacturing is anchored by facilities in Sweden and strategic contract‐manufacturing organizations, ensuring consistent supply of high‐complexity biologics and specialty pharmaceuticals to hospitals and specialty clinics worldwide.

Under the leadership of President and CEO Guido Oelkers, Sobi continues to pursue strategic acquisitions and licensing deals to expand its portfolio in rare disease areas. With a research and development center in Stockholm and ongoing investments in clinical trials, the company aims to deliver new therapeutic options for patients with limited treatment choices, reinforcing its position as a dedicated rare disease specialist in the global biopharmaceutical industry.

Key Stats

• Today's Range: $49.03 to $49.03
• 50-Day Range: $47.48 to $49.03
• 52-Week Range: $28.94 to $49.03
• Volume: N/A
• Average Volume: 114 shs
• Market Capitalization: $17.45 billion
• P/E Ratio: 163.43
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Swedish Orphan Biovitrum Stock Analysis - MarketRank™

Swedish Orphan Biovitrum scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Swedish Orphan Biovitrum has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Swedish Orphan Biovitrum has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 54.95%

Earnings Growth

Earnings for Swedish Orphan Biovitrum are expected to grow by 54.95% in the coming year, from $2.22 to $3.44 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Swedish Orphan Biovitrum is 163.43, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Swedish Orphan Biovitrum is 163.43, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.19.

Price to Book Value per Share Ratio

Swedish Orphan Biovitrum has a P/B Ratio of 4.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.07% of the float of Swedish Orphan Biovitrum has been sold short.

Short Interest Ratio / Days to Cover

Swedish Orphan Biovitrum has a short interest ratio ("days to cover") of 638.16, which indicates bearish sentiment.

Change versus previous month

Short interest in Swedish Orphan Biovitrum has recently decreased by 5.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Swedish Orphan Biovitrum does not currently pay a dividend.

Dividend Growth

Swedish Orphan Biovitrum does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.54

News Sentiment

Swedish Orphan Biovitrum has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Swedish Orphan Biovitrum this week, compared to 1 article on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Swedish Orphan Biovitrum insiders have not sold or bought any company stock.

Percentage Held by Institutions

Swedish Orphan Biovitrum has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/28/2026
• Today: 7/16/2026
• Next Earnings (Estimated): 7/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BIOVF
• CIK: N/A
• Web: www.sobi.com
• Phone: (468) 697-2000
• Fax: N/A
• Employees: 1,937
• Year Founded: 2010

Profitability

• EPS (Trailing Twelve Months): $0.30
• Trailing P/E Ratio: 163.43
• Forward P/E Ratio: 22.08
• P/E Growth: N/A
• Net Income: $48.85 million
• Net Margins: 3.37%
• Pretax Margin: 2.75%
• Return on Equity: 16.66%
• Return on Assets: 8.96%

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 0.70
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $2.89 billion
• Price / Sales: 6.05
• Cash Flow: $4.57 per share
• Price / Cash Flow: 10.72
• Book Value: $10.83 per share
• Price / Book: 4.53

Miscellaneous

• Outstanding Shares: 356,000,000
• Free Float: N/A
• Market Cap: $17.45 billion
• Optionable: Not Optionable
• Beta: 0.35